Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies

Summary

This will be a Phase 1, open label study of the pharmacokinetics (PK) and pharmacodynamics (PD) of clonidine, an alpha-2 adrenergic (a2a) agonist, in healthy volunteers. The primary aim is to show that the drug regimen is safe and reasonably well tolerated. The secondary aim is to demonstrate that safety can be monitored with home health devices.

Timeline

Start

2019-12-10

Primary completion

2020-03-17

Completion

2020-03-17

Drugs

Indications